- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03849443
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid in Patients at High Risk for Blood Transfusion After Spine Surgery
Study Overview
Status
Detailed Description
Background/Scientific review:
Open lumbar spine surgery is associated with the risk of moderate to significant blood loss. Because TXA has been shown to significantly reduce the need for blood products during total joint replacement, it is now the standard of care for these procedures at many institutions.1-3 Oral and IV TXA have been found to be similarly efficacious in total joint replacements, but oral TXA is cheaper and allows for ease of repeat dosing.1 Although low preoperative hemoglobin is a risk factor for transfusion, no studies that have compared standard single-dose oral or IV TXA dosing to repeated oral dosing of TXA in patients undergoing open spine surgery.
Study Design: Prospective, randomized, double-blinded study Inclusion Criteria: Any patient older than 18 years old and scheduled for an open posterior thoracolumbar spinal fusion procedure
Exclusion Criteria: Allergy to TXA, acquired disturbances of color vision, refusal of blood products, pre-op use of anticoagulant therapy within five days before surgery, a history of arterial or venous thromboembolic disease (such as DVT, PE, CVA, TIA), pregnancy, breastfeeding, major comorbidities (such as severe ischemic heart disease [New York Heart Association Class III or IV], previous myocardial infarction, severe pulmonary disease, renal impairment, or hepatic failure), patients who decline to participate, intolerance or sensitivity to Vitamin C.
Screening Procedures and Randomization: At the pre-operative clinic appointment and before the day of surgery, the study staff will assess the potential subject's eligibility, which would include asking for any intolerance/sensitivity to Vitamin C. Once eligibility is established, the potential subject will be approached regarding their participation in this clinical trial. The investigators will provide 48 hours before the date of surgery to allot for questions and consideration of the Informed Consent document. Once all patient questions have been answered patients willing to be in the study will sign the Informed Consent. Patients will be randomized, via standard randomization tables that provide a 1:1:1:1 distribution of subjects between the four groups through blocked randomization, no later than the morning of surgery to either of the four treatment groups: Placebo, Preoperative IV TXA, Preoperative-oral TXA only, or Full (pre-op and post-op) Oral TXA.
Sample Size Calculation: Sample size calculation determined that 151 patients per treatment group (604 patients total) are required to provide an alpha of 0.05 and beta of 0.80. This total of 604 patients includes a 10% drop-out rate to allow for protocol deviations.
Demographics/Patient Specifics: Age, sex, ASA score, weight, height, estimated intra-operative blood loss, intra-operative fluids (crystalloid, colloid), operative time, hospitalization days, BMI, pre-operative hemoglobin, hematocrit, PT/INR, PTT, and platelet count.
Treatment Groups:
Group 1 PLACEBO: three 250 mg tablets of ascorbic acid 2 hours prior to incision, placebo IV at time of incision intraoperatively, three 250 mg tablets of ascorbic acid given each day for three days postoperatively (while in the hospital as an inpatient).
Group 2 IV TXA: three 250 mg tablets of ascorbic acid 2 hours prior to incision, 1g IV TXA bolus at time of incision intraoperatively, three 250 mg tablets of ascorbic acid given each day for three days postoperatively (while in the hospital as an inpatient).
Group 3 Pre-Oral TXA: three 625mg tablets of oral TXA 2 hours prior to incision, placebo IV at time of incision intraoperatively, and three 250 mg tablets of ascorbic acid given each day for three days postoperatively (while in the hospital as an inpatient).
Group 4 Full Oral TXA: three 625mg tablets of oral TXA 2 hours prior to incision, placebo IV at time of incision intraoperatively, three 625mg tablets of oral TXA given each day for three days postoperatively (while in the hospital as an inpatient).
Outcome Measurements: (Assessed during hospital stay and at routine outpatient follow-up visit which occurs about 3 weeks after discharge and within 30 days of surgery) Number of patients transfused (primary outcome) and units transfused Post-operative reduction in hemoglobin and hematocrit
Postoperative blood loss will be determined primarily by the postoperative drop in hemoglobin, which is calculated as the patient's preoperative hemoglobin minus the patient's lowest postoperative hemoglobin. Secondarily, postoperative blood and hemoglobin loss will be calculated as a function of patient characteristics including sex, weight, and height as well as preoperative and postoperative hemoglobin balance, using the formulas previously described by Nadler et al and Good et al,5,6 which have been used in prior TXA studies.1,4 Cost comparison - Cost differences resulted from differences in the blood transfusion rate, length of hospital stay, and management of complications as well as from the cost of the TXA itself Complications - DVT/PE, return to the OR within 30 days, superficial or deep infection, and cerebrovascular accident, transient ischemic attack or MI
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Matthew Colman, MD
- Phone Number: 312-432-2468
- Email: an.research@rushortho.com
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 6060712
- Recruiting
- Rush University Medical Center
-
Contact:
- Matthew Colman, MD
- Phone Number: 312-432-2468
- Email: an.research@rushortho.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any patient older than 18 years old
- Scheduled for an open posterior thoracolumbar spinal fusion procedure
Exclusion Criteria:
- Allergy to TXA
- Acquired disturbances of color vision
- Refusal of blood products
- Pre-op use of anticoagulant therapy within five days before surgery
- History of arterial or venous thromboembolic disease (such as DVT, PE, CVA, TIA)
- Pregnancy
- Breastfeeding
- Severe ischemic heart disease [New York Heart Association Class III or IV]
- Previous myocardial infarction
- Severe pulmonary disease
- Renal impairment
- Hepatic failure
- Patients who decline to participate
- Intolerance or sensitivity to Vitamin C
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Group 1 PLACEBO
|
Oral method of placebo
|
Experimental: Group 2 IV TXA
|
Oral method of placebo
Intravenous methods to decrease blood loss
|
Experimental: Group 3 Pre-Oral TXA
|
Oral method of placebo
Oral method of treatment group
|
Experimental: Group 4 Full Oral TXA
|
Oral method of treatment group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Postoperative blood loss
Time Frame: During hospital stay and at routine outpatient follow-up visit which occurs about 3 weeks after discharge and within 30 days of surgery
|
During hospital stay and at routine outpatient follow-up visit which occurs about 3 weeks after discharge and within 30 days of surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
preoperative and postoperative hemoglobin balance
Time Frame: During hospital stay and at routine outpatient follow-up visit which occurs about 3 weeks after discharge and within 30 days of surgery
|
During hospital stay and at routine outpatient follow-up visit which occurs about 3 weeks after discharge and within 30 days of surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bryce Basques, MD, Rush University Medical Center
Publications and helpful links
General Publications
- Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011 Jan;93(1):39-46. doi: 10.1302/0301-620X.93B1.24984.
- Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962 Feb;51(2):224-32. No abstract available.
- Fillingham YA, Kayupov E, Plummer DR, Moric M, Gerlinger TL, Della Valle CJ. The James A. Rand Young Investigator's Award: A Randomized Controlled Trial of Oral and Intravenous Tranexamic Acid in Total Knee Arthroplasty: The Same Efficacy at Lower Cost? J Arthroplasty. 2016 Sep;31(9 Suppl):26-30. doi: 10.1016/j.arth.2016.02.081. Epub 2016 Mar 19.
- Irwin A, Khan SK, Jameson SS, Tate RC, Copeland C, Reed MR. Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures. Bone Joint J. 2013 Nov;95-B(11):1556-61. doi: 10.1302/0301-620X.95B11.31055.
- Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am. 2010 Nov 3;92(15):2503-13. doi: 10.2106/JBJS.I.01518.
- Good L, Peterson E, Lisander B. Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth. 2003 May;90(5):596-9. doi: 10.1093/bja/aeg111.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17081704-IRB01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Open Posterior Thoracolumbar Spinal Fusion Procedure
-
Shriners Hospitals for ChildrenSuspendedPosterior Spinal FusionUnited States, Canada
-
Joseph D. TobiasCompletedPosterior Spinal FusionUnited States
-
Yonsei UniversityCompletedElective Posterior Lumbar Spinal FusionKorea, Republic of
-
Yonsei UniversityCompletedPosterior Lumbar Spinal Fusion SurgeryKorea, Republic of
-
NuVasiveCompletedProximal Junctional Kyphosis | Spino-pelvic Alignment | Thoracolumbar Spinal FusionUnited States
-
University of Puerto RicoCompletedPain Management | Posterior Spinal FusionPuerto Rico
-
University of Colorado, DenverCompletedAdolescent Idiopathic Scoliosis | Posterior Spinal FusionUnited States
-
University of Colorado, DenverCompletedAdolescent Idiopathic Scoliosis | Posterior Spinal FusionUnited States
-
Tanta UniversityRecruitingIdiopathic Scoliosis | Posterior Spinal Fusion | Intrathecal Morphine | Mid-Transverse Process BlockEgypt
-
Sklifosovsky Institute of Emergency CareNot yet recruitingSpine Fusion | Spine Fracture | Thoracic Spine Fracture | Thoracolumbar Burst Fracture | Lumbar; Spine, Fracture | Fracture of Spine, Level UnspecifiedRussian Federation
Clinical Trials on Vitamin C 250 MG Oral Tablet
-
Daewoong Pharmaceutical Co. LTD.CompletedHealthy SubjectKorea, Democratic People's Republic of
-
Rajavithi HospitalRecruitingPregnancy Anemia | Vitamin C AnemiaThailand
-
Lexicon PharmaceuticalsCompletedIrritable Bowel SyndromeUnited States
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Idorsia Pharmaceuticals Ltd.Completed
-
Cassava Sciences, Inc.National Institute on Aging (NIA)Completed
-
Enteris BioPharma Inc.Syneos Health; ParexelRecruitingEndometriosisUnited States
-
Fulcrum TherapeuticsCompletedHealthy Adult SubjectsUnited States
-
Massachusetts General HospitalWithdrawnObese | Disorder of Vitamin C | Growth Hormone Secretion AbnormalityUnited States
-
Cara Therapeutics, Inc.RecruitingChronic Kidney Diseases | PruritusUnited States